Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More Details
Excellent balance sheet with high growth potential.
Share Price & News
How has Inovio Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: INO's weekly volatility has decreased from 19% to 12% over the past year.
7 Day Return
1 Year Return
Return vs Industry: INO underperformed the US Biotechs industry which returned 19.7% over the past year.
Return vs Market: INO underperformed the US Market which returned 50.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Inovio Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhy We Think Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) CEO Compensation Is Not Excessive At All
1 month ago | Simply Wall StDid Business Growth Power Inovio Pharmaceuticals' (NASDAQ:INO) Share Price Gain of 112%?
3 months ago | Simply Wall StInovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?
Is Inovio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate INO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate INO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: INO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: INO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INO is good value based on its PB Ratio (2.4x) compared to the US Biotechs industry average (3.3x).
How is Inovio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: INO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: INO's is expected to become profitable in the next 3 years.
Revenue vs Market: INO's revenue (45% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: INO's revenue (45% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INO's Return on Equity is forecast to be high in 3 years time
How has Inovio Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INO is currently unprofitable.
Growing Profit Margin: INO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INO is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare INO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).
Return on Equity
High ROE: INO has a negative Return on Equity (-32.45%), as it is currently unprofitable.
How is Inovio Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: INO's short term assets ($588.4M) exceed its short term liabilities ($41.5M).
Long Term Liabilities: INO's short term assets ($588.4M) exceed its long term liabilities ($31.7M).
Debt to Equity History and Analysis
Debt Level: INO's debt to equity ratio (2.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if INO's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INO has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 28.6% each year.
What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
J. Kim (51 yo)
Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD4.71M) is about average for companies of similar size in the US market ($USD3.77M).
Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.
Experienced Management: INO's management team is considered experienced (2.2 years average tenure).
Experienced Board: INO's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.5%.
Inovio Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Inovio Pharmaceuticals, Inc.
- Ticker: INO
- Exchange: NasdaqGS
- Founded: 1979
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.372b
- Shares outstanding: 209.40m
- Website: https://www.inovio.com
Number of Employees
- Inovio Pharmaceuticals, Inc.
- 660 West Germantown Pike
- Suite 110
- Plymouth Meeting
- United States
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillom...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 22:12|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.